Re Agreement

Ardana PLC
13 February 2007

                          ARDANA SIGNS AGREEMENT WITH

                       TWINPHARMA TO MARKET STRIANTTM SR

                              IN THE NETHERLANDS



Edinburgh, UK, 13 February 2007:  Ardana plc (LSE:ARA) today announces that it
has signed an agreement granting TwinPharma BV ('TwinPharma') exclusive rights
to market StriantTM SR in the Netherlands.



StriantTM SR is a mucoadhesive buccal (gum surface) testosterone replacement
therapy for confirmed male hypogonadism (i.e. those suffering from a deficiency
or absence of testosterone). StriantTM SR is the first-to-market buccal adhesive
tablet and is marketed to urologists and endocrinologists by Ardana's own sales
force in the UK, and via partners in Germany, Ireland and the Nordic Region.



TwinPharma will shortly launch StriantTM SR in the Netherlands as pricing and
reimbursement has now been agreed with the Netherlands Health Authority.



Dr. Maureen Lindsay, Chief Executive of Ardana, said: 'Today's announcement
shows Ardana's continued commitment to expand its product portfolio into the
European market with specialist collaborations in each country.  We are very
pleased to be working with TwinPharma to ensure that we continue to introduce
novel therapies for indications where there are unmet patient needs.'



Gert van Alewijk and Bauke Buwalda, founders of TwinPharma, said:  'We set up
TwinPharma with the ambition to introduce novel medicines into the Dutch market.
StriantTM SR is a truly novel therapy and fits perfectly with the strategic view
of TwinPharma. The collaboration with Ardana Bioscience is very professional and
inspiring and we are looking forward to a successful and pleasant cooperation.'





For more information contact:
Ardana                                     Financial Dynamics
Maureen Lindsay                            (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550                 Julia Phillips/John Gilbert
                                           Tel: [phone]
TwinPharma
Bauke Buwalda
Tel: + 31 (0) 348 493015





About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.



Since its foundation, Ardana has built a broad and balanced portfolio to manage
risk and actively pursues product and technology in-licensing and outlicensing
to maintain a robust pipeline.



Ardana's lead products are summarised below:



  • Emselex(R), a once a day treatment for the symptoms of overactive bladder
    syndrome, which Ardana has exclusive UK marketing and promotion rights and
    is being distributed in collaboration with Novartis UK Limited;
  • StriantTM SR, a testosterone replacement therapy that has been launched by
    Ardana through its own sales force in the UK and through marketing partners
    in certain European countries, as a treatment for men with confirmed
    hypogonadism;
  • Teverelix LA, in development for three initial indications (prostate
    cancer, benign prostatic hyperplasia and endometriosis);
  • Testosterone Cream, a trans dermal testosterone delivery system in
    development for the treatment of male hypogonadism, in Phase II trials;
  • InvicorpTM, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe and has been launched in Denmark.
  • EP01572 a growth hormone secretagogue in late stage development for the
    diagnosis of growth hormone deficiency



In addition, Ardana has a strong portfolio of follow-on products in development.
  Ardana is listed on the Main Market of the London Stock Exchange.



For further information please see www.ardana.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange